http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007144422-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60417e67a8d3c2edac58b31c36b2955e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae84948901b77f34fd51c41264d8d19c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbe66809e1235cc773face7b299c5d7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ecc70b0fdb40966a0ae7b0eb843c833
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
filingDate 2007-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2007d2b73a1cd8c28fa140f5034995a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90154ea04137044b71641863ab2cf2e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1bbefe6aa75299409b8c0c42f846b2f
publicationDate 2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007144422-A3
titleOfInvention Combination preparations comprising bifeprunox and l-dopa
abstract The invention concerns the use of a combination preparation of bifeprunox or its N-oxide, or pharmacologically acceptable salts of those compounds: and L-DOPA, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function, in particular Parkinson's disease and restless leg syndrome.
priorityDate 2006-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016898-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226486846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411642
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6047

Total number of triples: 32.